VCRE
Vicore Pharma Holding AB (publ)
Price Chart
Latest Quote
$9.35
-0.05 (-0.53%)
Current Price
| Previous Close | $9.40 |
| Open | $9.33 |
| Day High | $9.91 |
| Day Low | $9.31 |
| Volume | 24,172 |
Stock Information
Note: Financial values converted from SEK to USD
| Shares Outstanding | 28.16M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $263.34M |
| EPS (TTM) | $-2.06 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Employees | 46 |
Financial Ratios
| Quick Ratio | 12.50 |
| Current Ratio | 12.68 |
Returns & Margins
| ROA | -34.35% |
| ROE | -56.99% |
| Gross Margin | 100.00% |
Ownership
| Institutional Ownership | 1.28% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
Analyst Data
| Recommendation | strong_buy |
| Target Price | $29.90 |
Technical Indicators
| SMA20 | $9.17 |
| SMA50 | $10.28 |
| RSI | 59.30 |
| ATR | 0.6421 |
| Shares Float | 20.08M |
| Short Ratio | 0.14 |
| Volatility | 0.09 |
| Rel Volume | 0.90 |
Performance History
| Week | +3.89% |
| Month | -2.50% |
| Quarter | -15.23% |
| YTD | -42.46% |
| 10 Years | -42.46% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $9.35 | 24,200 |
| 2026-10-26 | $9.40 | 4,000 |
| 2026-10-23 | $9.38 | 28,400 |
| 2026-10-22 | $10.32 | 103,300 |
| 2026-10-21 | $9.28 | 9,800 |
| 2026-10-20 | $9.00 | 18,800 |
| 2026-10-19 | $8.85 | 3,600 |
| 2026-10-16 | $8.98 | 3,300 |
| 2026-10-15 | $9.09 | 38,500 |
| 2026-10-14 | $9.08 | 23,100 |
| 2026-10-13 | $8.95 | 27,800 |
| 2026-10-12 | $9.23 | 43,500 |
| 2026-10-09 | $9.00 | 31,000 |
| 2026-10-08 | $8.82 | 21,100 |
| 2026-10-07 | $8.66 | 32,000 |
| 2026-10-06 | $8.74 | 22,800 |
| 2026-10-05 | $9.00 | 11,800 |
| 2026-10-02 | $9.33 | 27,500 |
| 2026-10-01 | $9.43 | 41,100 |
| 2026-09-30 | $9.51 | 20,400 |
| 2026-09-29 | $9.52 | 65,500 |
| 2026-09-28 | $9.59 | 27,500 |
About Vicore Pharma Holding AB (publ)
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. It has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.
đ° Latest News
No news articles available at the moment. Check back later for updates on VCRE.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $384,429 | $11,012,780 | $0 | $0 |
| Operating Revenue | $384,429 | $11,012,780 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $6,043 | $806 | $201 | $806 |
| Total Expenses | $46,153,845 | $30,184,882 | $32,318,327 | $28,954,951 |
| Net Non Operating Interest Income Expense | $2,399,836 | $2,122,367 | $1,061,133 | $91,147 |
| Interest Expense Non Operating | $6,043 | $806 | $201 | $806 |
| Operating Expense | $46,153,845 | $30,184,882 | $32,318,327 | $28,954,951 |
| Other Operating Expenses | $-207,372 | $385,638 | $62,141 | - |
| General And Administrative Expense | $6,839,957 | $5,080,365 | $3,718,699 | $2,858,291 |
| Selling And Marketing Expense | - | $0 | $772,685 | $921,441 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-48,088,781 | $-16,983,969 | $-31,316,515 | $-29,048,414 |
| Net Interest Income | $2,399,836 | $2,122,367 | $1,061,133 | $91,147 |
| Interest Income | $2,405,879 | $2,123,172 | $1,061,334 | $91,953 |
| Normalized Income | $-48,088,781 | $-16,983,969 | $-31,280,661 | $-29,001,280 |
| Net Income From Continuing And Discontinued Operation | $-48,088,781 | $-16,983,969 | $-31,316,515 | $-29,048,414 |
| Total Operating Income As Reported | $-45,562,044 | $-19,557,740 | $-32,380,468 | $-29,280,361 |
| Net Income Common Stockholders | $-48,088,781 | $-16,983,969 | $-31,316,515 | $-29,048,414 |
| Net Income | $-48,088,781 | $-16,983,969 | $-31,316,515 | $-29,048,414 |
| Net Income Including Noncontrolling Interests | $-48,088,781 | $-16,983,969 | $-31,316,515 | $-29,048,414 |
| Net Income Continuous Operations | $-48,088,781 | $-16,983,969 | $-31,316,515 | $-29,048,414 |
| Pretax Income | $-48,088,781 | $-17,009,752 | $-31,355,190 | $-29,087,089 |
| Interest Income Non Operating | $2,405,879 | $2,123,172 | $1,061,334 | $91,953 |
| Operating Income | $-45,769,416 | $-19,172,102 | $-32,318,327 | $-28,954,951 |
| Gross Profit | $384,429 | $11,012,780 | $0 | $0 |
| Per Share | ||||
| Diluted EPS | $-2.00 | $-1.24 | $-3.20 | $-3.91 |
| Basic EPS | $-2.00 | $-1.24 | $-3.20 | $-3.91 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-48,082,739 | $-16,783,043 | $-30,974,387 | $-28,675,366 |
| Total Unusual Items | $-4,926,574 | $0 | $-35,855 | $-47,135 |
| Total Unusual Items Excluding Goodwill | $-4,926,574 | $0 | $-35,855 | $-47,135 |
| Reconciled Depreciation | $0 | $225,904 | $344,747 | $363,782 |
| EBITDA (Bullshit earnings) | $-48,082,739 | $-16,783,043 | $-31,010,241 | $-28,722,501 |
| EBIT | $-48,082,739 | $-17,008,946 | $-31,354,989 | $-29,086,283 |
| Diluted Average Shares | $2,415,984 | $1,378,229 | $972,492 | $747,511 |
| Basic Average Shares | $2,415,984 | $1,378,229 | $972,492 | $747,511 |
| Diluted NI Availto Com Stockholders | $-48,088,781 | $-16,983,969 | $-31,316,515 | $-29,048,414 |
| Otherunder Preferred Stock Dividend | $0 | $0 | $0 | $0 |
| Tax Provision | $0 | $-25,783 | $-38,675 | $-38,675 |
| Research And Development | $39,313,889 | $25,104,517 | $27,826,943 | $25,175,218 |
| Selling General And Administration | $6,839,957 | $5,080,365 | $4,491,384 | $3,779,732 |
Fetched: 2026-10-26
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $110,329,427 | $113,740,341 | $45,641,105 | $22,256,297 |
| Total Assets | $122,734,994 | $120,412,204 | $50,139,741 | $34,042,366 |
| Total Non Current Assets | $172,525 | $0 | $225,904 | $6,870,473 |
| Goodwill And Other Intangible Assets | $0 | $0 | $223,386 | $6,858,690 |
| Current Assets | $122,562,469 | $120,412,204 | $49,913,838 | $27,171,893 |
| Prepaid Assets | $3,418,568 | $1,995,969 | $976,835 | $590,895 |
| Other Receivables | $1,635,913 | $1,989,624 | $326,014 | $219,559 |
| Cash Cash Equivalents And Short Term Investments | $117,507,987 | $116,426,611 | $48,610,989 | $26,361,439 |
| Cash And Cash Equivalents | $58,228,060 | $116,426,611 | $33,600,530 | $25,863,907 |
| Other Intangible Assets | - | - | $223,386 | $6,858,690 |
| Investmentin Financial Assets | - | - | - | $0 |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | - | - | - | $0 |
| Cash Equivalents | - | - | - | $25,863,505 |
| Cash Financial | - | - | - | $403 |
| Non Current Deferred Taxes Assets | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $12,405,567 | $6,671,863 | $4,275,250 | $4,927,379 |
| Total Non Current Liabilities Net Minority Interest | $477,490 | $55,998 | $150,166 | $252,291 |
| Other Non Current Liabilities | $85,306 | - | - | - |
| Non Current Deferred Taxes Liabilities | $29,308 | $31,725 | $59,724 | $91,147 |
| Current Liabilities | $11,928,077 | $6,615,866 | $4,125,084 | $4,675,088 |
| Other Current Liabilities | $1,152,884 | $1,784,065 | $512,438 | $377,782 |
| Payables | $3,981,666 | $3,212,606 | $1,918,419 | $2,442,842 |
| Total Tax Payable | $6,144 | $194,581 | $114,009 | $76,543 |
| Accounts Payable | $3,975,522 | $3,018,025 | $1,804,409 | $2,366,298 |
| Equity | ||||
| Common Stock Equity | $110,329,427 | $113,740,341 | $45,864,491 | $29,114,987 |
| Total Equity Gross Minority Interest | $110,329,427 | $113,740,341 | $45,864,491 | $29,114,987 |
| Stockholders Equity | $110,329,427 | $113,740,341 | $45,864,491 | $29,114,987 |
| Retained Earnings | $-193,465,005 | $-145,276,717 | $-128,337,264 | $-96,953,471 |
| Other | ||||
| Ordinary Shares Number | $28,353,843 | $23,625,630 | $11,564,737 | $8,472,298 |
| Share Issued | $28,353,843 | $23,625,630 | $11,564,737 | $8,472,298 |
| Tangible Book Value | $110,329,427 | $113,740,341 | $45,641,105 | $22,256,297 |
| Invested Capital | $110,329,427 | $113,740,341 | $45,864,491 | $29,114,987 |
| Working Capital | $110,634,392 | $113,796,338 | $45,788,754 | $22,496,804 |
| Total Capitalization | $110,329,427 | $113,740,341 | $45,864,491 | $29,114,987 |
| Additional Paid In Capital | $289,617,490 | $247,204,199 | $168,575,716 | $121,946,798 |
| Capital Stock | $14,176,942 | $11,812,859 | $5,626,039 | $4,121,660 |
| Common Stock | $14,176,942 | $11,812,859 | $5,626,039 | $4,121,660 |
| Long Term Provisions | $477,490 | $55,998 | $90,442 | $161,144 |
| Current Provisions | $166,079 | $33,035 | $219,256 | $12,791 |
| Other Short Term Investments | $59,279,927 | - | $15,010,459 | $497,532 |
| Net PPE | - | $0 | $2,518 | $5,439 |
| Accumulated Depreciation | - | $-14,805 | $-12,287 | $-9,366 |
| Gross PPE | - | $14,805 | $14,805 | $14,805 |
| Other Properties | - | $14,805 | $14,805 | $14,805 |
| Non Current Deferred Revenue | - | - | - | $0 |
Fetched: 2026-10-26
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-37,842,342 | $-16,612,532 | $-25,136,745 | $-30,508,479 |
| Operating Activities | ||||
| Operating Cash Flow | $-37,842,342 | $-16,612,532 | $-25,136,745 | $-30,206,334 |
| Investing Activities | ||||
| Investing Cash Flow | $-60,479,946 | $15,010,358 | $-14,548,782 | $7,452,908 |
| Net Other Investing Changes | $-250,579 | - | - | - |
| Capital Expenditure | - | - | - | $-302,145 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $45,835,183 | $88,845,009 | $50,398,377 | $20,142,995 |
| Financing Cash Flow | $43,362,228 | $84,002,633 | $47,422,149 | $18,837,729 |
| Net Common Stock Issuance | $45,835,183 | $88,845,009 | $50,398,377 | $20,142,995 |
| Common Stock Issuance | $45,835,183 | $88,845,009 | $50,398,377 | $20,142,995 |
| Net Other Financing Charges | - | - | $-6,345 | $-25,380 |
| Other | ||||
| End Cash Position | $58,228,060 | $116,426,611 | $33,600,530 | $25,863,907 |
| Beginning Cash Position | $116,426,611 | $33,600,530 | $25,863,907 | $29,630,245 |
| Effect Of Exchange Rate Changes | $-3,238,490 | $425,621 | $0 | $149,360 |
| Changes In Cash | $-54,960,061 | $82,400,460 | $7,736,622 | $-3,915,697 |
| Net Investment Purchase And Sale | $-60,479,946 | $15,010,358 | $-14,548,782 | $7,755,053 |
| Sale Of Investment | $38,618,955 | $21,537,696 | $5,497,426 | $7,755,053 |
| Purchase Of Investment | $-99,098,902 | $-6,527,337 | $-20,046,208 | $0 |
| Interest Received Cfo | $1,861,817 | $2,106,957 | $1,050,558 | $120,254 |
| Interest Paid Cfo | $-5,942 | $-705 | $-201 | $-806 |
| Change In Working Capital | $4,110,279 | $-185,013 | $-1,072,212 | $-2,108,972 |
| Change In Payable | $4,420,380 | $3,400,641 | $-640,749 | $-1,948,029 |
| Change In Receivables | $-310,101 | $-3,585,655 | $-431,463 | $-160,943 |
| Other Non Cash Items | $-99,506 | $44,717 | $-67,278 | - |
| Depreciation And Amortization | $0 | $225,904 | $344,747 | $363,782 |
| Pension And Employee Benefit Expense | $1,969,683 | $753,348 | $687,984 | $498,338 |
| Net Foreign Currency Exchange Gain Loss | $-116,628 | $0 | - | - |
| Net Income From Continuing Operations | $-45,562,044 | $-19,557,740 | $-32,380,468 | $-29,280,361 |
| Amortization Cash Flow | - | $223,386 | $335,079 | $335,079 |
| Depreciation | - | $225,904 | $344,747 | $28,704 |
| Net Intangibles Purchase And Sale | - | - | $0 | $-302,145 |
| Purchase Of Intangibles | - | - | $0 | $-302,145 |
| Gain Loss On Sale Of PPE | - | - | $0 | $201,430 |
Fetched: 2026-10-26